BioTuesdays
Acutes-Medical-Logo
Markets

Analysts cut Acutus Medical PT to $8 and $10

Analysts for BTIG and Canaccord Genuity reduced their price targets for Acutus Medical (NASDAQ:AFIB) to $8 from $20 and to $10 from $18, respectively, but maintain their “buy” ratings, after the company reported third...

November 12, 2021
T2 Biosystems Logo
Markets

AGP cuts T2 Biosystems PT to 88 cents from $1.25

Alliance Global Partners reduced its price target for T2 Biosystems (NASDAQ:TTOO) to 88 cents from $1.25 and maintained a “neutral” rating after the company reported mixed third quarter results. The stock closed at 79...

November 8, 2021
PharmaCyte Logo
Markets

HCW starts PharmaCyte Biotech at neutral

H.C. Wainwright initiated coverage of PharmaCyte Biotech (NASDAQ:PMCB) with a “neutral” rating without a price target, as “we await the FDA’s clinical hold to be lifted.” The stock closed at $2.93 on Oct. 5. “Once...

November 8, 2021
Deciphera Pharma
Markets

Stifel cuts Deciphera Pharma to hold; PT to $10 from $60

Stifel downgraded Deciphera Pharmaceuticals (NASDAQ:DCPH) to “hold” from “buy” and slashed its price target to $10 from $60 after the failure of the company’s Qinlock in 2L gastrointestinal stromal tumor (GIST).  Shares...

November 8, 2021
Pliant Therapeutics
Markets

HCW starts Pliant Therapeutics at buy; PT $45

H.C. Wainwright initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a “buy” rating and $45 price target. The stock closed at $16.81 on Nov. 2. Pliant is a clinical-stage biopharmaceutical company focused on the...

November 3, 2021
Theseus Pharmaceuticals
Markets

SVB Leerink starts Theseus Pharma at OP; PT $28

SVB Leerink launched coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with an “outperform” rating and $28 price target. The stock closed at $17.12 on Oct. 29. Theseus is a biopharmaceutical company focused on “pan...

November 1, 2021
Agrify
Markets

AGP starts Agrify at buy; PT $32

Alliance Global Partners initiated coverage of Agrify (NASDAQ:AGFY) with a “buy” rating and $32 price target. The stock closed at $16 on Oct. 29. “We see Agrify as an ancillary play on cannabis with the company’s...

November 1, 2021
AugMedix
Markets

WB starts Augmedix at OP

William Blair launched coverage of Augmedix (NASDAQ:AUGX) with an “outperform” rating. The stock closed at $3.63 on Oct. 29. Augmedix provides a virtual medical documentation and live clinical support service, which...

November 1, 2021
Sigilon Therapeutics
Markets

BTIG starts Sigilon Therapeutics at buy; PT $14

BTIG launched coverage of Sigilon Therapeutics (NASDAQ:SGTX) with a “buy” rating and price target of $14. The stock closed at $5.38 on Oct. 28. Sigilon is developing shielded living therapeutics (SLTs) as a “functional...

October 29, 2021
Protagenic Therapeutics
Markets

Maxim starts Protagenic Therapeutics at buy; PT $4

Maxim Group initiated coverage of Protagenic Therapeutics (NASDAQ:PTIX) with a “buy” rating and price target of $4. The stock closed at $1.80 on Oct. 28. Protagenic is developing its lead asset, PT00114, for the...

October 29, 2021
biophytis
Markets

HCW starts Biophytis at buy; PT $15

H.C. Wainwright initiated coverage of Biophytis SA of France (NASDAQ:BPTS) with a “buy” rating and $15 price target. The stock closed at $6.09 on Oct. 22. As a spin-off from Sorbonne University in 2006, Biophytis has...

October 25, 2021
Tempest Therapeutics
Markets

WB starts Tempest Therapeutics at OP

William Blair initiated coverage of Tempest Therapeutics (NASDAQ:TPST) with an “outperform” rating based on the potential of the company’s three first-in-class programs, including the dual EP2/EP4 antagonist, TPST-1495...

October 21, 2021
Jasper Therapeutics
Markets

WB starts Jasper Therapeutics at OP

William Blair launched coverage of Jasper Therapeutics (NASDAQ:JSPR) with an “outperform” rating based on the potential for JSP191 to transform the bone marrow transplant field through safer and more-effective...

October 21, 2021
Atea Pharmaceuticals
Markets

SVB Leerink cuts Atea Pharma PT to $20 from $60

SVB Leerink slashed its price target for Atea Pharmaceuticals (NASDAQ:AVIR) to $20 from $60 but maintained its “outperform” rating after the company’s Phase 2 MOONSONG trial in COVID-19 outpatients did not hit its...

October 20, 2021
Vicarious-Surgical
Markets

BTIG starts Vicarious Surgical at buy; PT $15

BTIG initiated coverage of Vicarious Surgical (NYSE:RBOT) with a “buy” rating and $15 price target. The stock closed at $10.57 on Oct.15. Vicarious Surgical is a pre-commercial development-stage surgical robotics...

October 18, 2021
Kazia Therapeutics New
Markets

Maxim starts Kazia Therapeutics at buy; PT $18

Maxim Group initiated coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and $18 price target. The stock closed at $10.71 on Oct. 13. Kazia is developing two oncology drug candidates: paxalisib, for brain...

October 14, 2021
Progenity-New
Markets

HCW starts Progenity at buy; PT $4

H.C. Wainwright launched coverage of Progenity (NASDAQ:PROG) with a “buy” rating and price target of $4. The stock closed at $2.04 on Oct. 13. Progenity’s differentiated R&D pipeline primarily focuses on employing...

October 14, 2021
Renovacor New.jpg
Markets

Ladenburg starts Renovacor at buy; PT $22

Ladenburg Thalmann initiated coverage of Renovacor (NASDAQ:RCOR) with a “buy” rating and $22 price target. The stock closed at $7.93 on Oct. 13. Renovacor is a preclinical-stage biotech company focused on developing...

October 14, 2021